IL243572B - Drug combination for the treatment of melanoma - Google Patents

Drug combination for the treatment of melanoma

Info

Publication number
IL243572B
IL243572B IL24357216A IL24357216A IL243572B IL 243572 B IL243572 B IL 243572B IL 24357216 A IL24357216 A IL 24357216A IL 24357216 A IL24357216 A IL 24357216A IL 243572 B IL243572 B IL 243572B
Authority
IL
Israel
Prior art keywords
melanoma
treatment
pharmaceutical combination
pharmaceutical
combination
Prior art date
Application number
IL24357216A
Other languages
English (en)
Hebrew (he)
Other versions
IL243572A0 (en
Inventor
Rathos Maggie
Agarwal Veena
Periyasamy Giridharan
Srivastava Ankita
Srinivasa Sreesha
Original Assignee
Piramal Entpr Ltd
Rathos Maggie
Agarwal Veena
Periyasamy Giridharan
Srivastava Ankita
Srinivasa Sreesha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Piramal Entpr Ltd, Rathos Maggie, Agarwal Veena, Periyasamy Giridharan, Srivastava Ankita, Srinivasa Sreesha filed Critical Piramal Entpr Ltd
Publication of IL243572A0 publication Critical patent/IL243572A0/en
Publication of IL243572B publication Critical patent/IL243572B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL24357216A 2013-07-12 2016-01-11 Drug combination for the treatment of melanoma IL243572B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361845749P 2013-07-12 2013-07-12
PCT/IB2014/063022 WO2015004636A1 (en) 2013-07-12 2014-07-11 A pharmaceutical combination for the treatment of melanoma

Publications (2)

Publication Number Publication Date
IL243572A0 IL243572A0 (en) 2016-02-29
IL243572B true IL243572B (en) 2019-10-31

Family

ID=52279411

Family Applications (1)

Application Number Title Priority Date Filing Date
IL24357216A IL243572B (en) 2013-07-12 2016-01-11 Drug combination for the treatment of melanoma

Country Status (12)

Country Link
US (4) US11007174B2 (enExample)
EP (1) EP3019166B1 (enExample)
JP (5) JP6568060B2 (enExample)
CN (3) CN117731786A (enExample)
AR (1) AR096892A1 (enExample)
AU (1) AU2014288857B2 (enExample)
CA (1) CA2917742C (enExample)
DK (1) DK3019166T3 (enExample)
ES (1) ES2733929T3 (enExample)
IL (1) IL243572B (enExample)
TW (4) TWI839690B (enExample)
WO (1) WO2015004636A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI839690B (zh) 2013-07-12 2024-04-21 印度商皮拉馬爾企業有限公司 治療黑色素瘤的藥物組合的用途
WO2016197129A1 (en) 2015-06-05 2016-12-08 The Board Of Trustees Of The University Of Illinois Pac-1 combination therapy
CN108135854B (zh) * 2015-06-30 2022-03-11 基因泰克公司 含有药物的立即释放片剂和用于形成片剂的方法
JP6987084B2 (ja) * 2016-03-16 2021-12-22 ディセルナ ファーマシューティカルズ インコーポレイテッド β−カテニン関連疾患又は障害の治療のための組成物及び方法
AU2018209164B2 (en) 2017-01-17 2021-11-04 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
CN110799245B (zh) * 2017-05-16 2022-08-09 生物医学谷探索股份有限公司 用于治疗具有非典型braf突变的癌症的组合物和方法
AU2018368453B2 (en) 2017-11-17 2024-05-30 The Board Of Trustees Of The University Of Illinois Cancer therapy by degrading dual MEK signaling
CN107827726B (zh) * 2017-11-28 2020-09-15 辽宁中医药大学 马齿苋中化合物Oleracone E及其提取分离方法
CN108591464B (zh) * 2018-06-28 2020-06-23 宁波奥克斯高科技有限公司 一种气体绝缘开关柜用密封结构
KR20210084442A (ko) 2018-10-05 2021-07-07 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 포도막 흑색종 치료를 위한 병용 요법
EP3952861A4 (en) 2019-04-11 2023-01-11 MEI Pharma, Inc. VORUCICLIB POLYMORPHS AND PROCESSES FOR THEIR PRODUCTION AND USE
US20240000789A1 (en) * 2020-05-12 2024-01-04 Novartis Ag Therapeutic combinations comprising a craf inhibitor
CN112168821B (zh) * 2020-11-09 2022-10-14 中南大学湘雅医院 一种治疗维罗非尼耐药的黑色素瘤的联合用药物及其应用
CN117043159A (zh) * 2020-11-19 2023-11-10 梅制药公司 Kras突变型癌症的治疗
JP2024500288A (ja) * 2020-11-19 2024-01-09 メイ ファーマ，インク． Ｋｒａｓ変異癌の治療

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN164232B (enExample) 1986-04-11 1989-02-04 Hoechst India
US5116954A (en) 1988-04-06 1992-05-26 Lipha, Lyonnaise Industrielle Pharmaceutique Pharmaceutically useful flavonoic compounds containing at least one substituent on the benzopyranone ring moiety
USH1427H (en) 1988-04-06 1995-04-04 Briet; Phillipe Substituted flavonoid compounds, their salts, their manufacture and their use in combination with interleukin-2
US5284856A (en) 1988-10-28 1994-02-08 Hoechst Aktiengesellschaft Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives
US5723313A (en) 1995-09-27 1998-03-03 St. Jude Children's Research Hospital ARF-p19, a novel regulator of the mammalian cell cycle
US5733920A (en) 1995-10-31 1998-03-31 Mitotix, Inc. Inhibitors of cyclin dependent kinases
US5849733A (en) 1996-05-10 1998-12-15 Bristol-Myers Squibb Co. 2-thio or 2-oxo flavopiridol analogs
US6281223B1 (en) 1999-04-13 2001-08-28 Supergen, Inc. Radioenhanced camptothecin derivative cancer treatments
HUP0300382A3 (en) 2000-03-29 2006-11-28 Cyclacel Ltd 2-substituted 4-heteroaryl-pyrimidines and their use in the treatmetn of proliferative disorders and pharmaceutical compositions containing the compounds
EP1280789A1 (en) 2000-05-03 2003-02-05 LG Life Sciences Ltd. Cdk inhibitors having 3-hydroxychromen-4-one structure
IL153688A0 (en) 2000-06-28 2003-07-06 Teva Pharma Carvedilol
US7884127B2 (en) 2002-07-08 2011-02-08 Pirimal Life Sciences Ltd. Inhibitors of cyclin dependent kinases and their use
TWI331034B (en) 2002-07-08 2010-10-01 Piramal Life Sciences Ltd Inhibitors of cyclin-dependent kinases and their use
US7915301B2 (en) 2002-07-08 2011-03-29 Piramal Life Science Limited Inhibitors of cyclin dependent kinases and their use
US7271193B2 (en) * 2002-07-08 2007-09-18 Nicholas Piramal India, Ltd. Inhibitors of cyclin-dependent kinases and their use
CA2502979A1 (en) 2002-11-06 2004-05-21 Cyclacel Limited Pharmaceutical composition comprising a cdk inhibitor and gemcitabine
GB0328180D0 (en) 2003-12-04 2004-01-07 Cyclacel Ltd Combination
WO2005055952A2 (en) 2003-12-08 2005-06-23 The Arizona Board Of Regents On Behalf Of The University Of Arizona Synergistic anti-cancer compositions
CA2600797A1 (en) 2005-03-11 2006-09-21 The Regents Of The University Of Michigan Chromen-4-one inhibitors of anti-apoptotic bcl-2 family members and the uses thereof
DK2395004T3 (en) * 2005-06-22 2016-03-21 Plexxikon Inc Pyrrolo [2,3-b] pyridine derivatives as protein kinase inhibitors
EP2046738B1 (en) * 2006-06-21 2014-06-11 Piramal Enterprises Limited Enantiomerically pure flavone derivatives for the treatment of proliferative disorders and processes for their preparation
CA2658215C (en) 2006-07-07 2013-08-27 Piramal Life Sciences Limited An enantioselective synthesis of pyrrolidines-substituted flavones
GB0706633D0 (en) 2007-04-04 2007-05-16 Cyclacel Ltd Combination
US8822526B2 (en) * 2007-05-15 2014-09-02 Piramal Enterprises Limited Synergistic pharmaceutical combination for the treatment of cancer
US20100152129A1 (en) * 2008-03-31 2010-06-17 Periyasamy Giridharan Novel synergistic combination of gemcitabine with P276-00 or P1446A in treatment of cancer
TWI461194B (zh) 2009-05-05 2014-11-21 Piramal Entpr Ltd 吡咯啶取代黃酮作為輻射致敏劑
EP2538941A1 (en) 2010-02-26 2013-01-02 Piramal Enterprises Limited Pyrrolidine substituted flavones for the treatment of inflammatory disorders
CN101841463B (zh) * 2010-03-05 2012-05-16 清华大学 基于sctp的多路径并发传输方法
US20130165456A1 (en) * 2010-08-26 2013-06-27 Tona M. Gilmer Combination
CA2818544A1 (en) * 2010-11-19 2012-05-24 Glaxosmithkline Intellectual Property (No.2) Limited Method of treatment with braf inhibitor
MX2013005661A (es) 2010-11-19 2013-09-13 Piramal Entpr Ltd Combinacion farmaceutica de paclitaxel y un inhibidor cdk (quinasa dependiente de ciclina).
WO2012123889A1 (en) * 2011-03-14 2012-09-20 Piramal Healthcare Limited A synergistic pharmaceutical combination for the treatment of pancreatic cancer
TW201300105A (zh) 2011-05-31 2013-01-01 Piramal Life Sciences Ltd 治療頭頸鱗狀細胞癌之相乘藥物組合物
US20120321637A1 (en) * 2011-06-20 2012-12-20 The Board Of Regents Of The University Of Texas System Combination cancer therapy with herv inhibition
CA2840017A1 (en) 2011-06-24 2012-12-27 Piramal Enterprises Limited Compounds for the treatment of cancers associated with human papillomavirus
TW201338774A (zh) 2012-01-13 2013-10-01 Piramal Entpr Ltd 口腔粘膜炎預防或治療化合物
WO2014049515A1 (en) 2012-09-25 2014-04-03 Piramal Enterprises Limited Pyrrolidine substituted flavones for treatment of renal cystic diseases
WO2014128523A1 (en) 2013-02-19 2014-08-28 Piramal Enterprises Limited A process for preparation of an intermediate of the pyrrolidine substituted flavones
TWI839690B (zh) 2013-07-12 2024-04-21 印度商皮拉馬爾企業有限公司 治療黑色素瘤的藥物組合的用途
WO2015181737A1 (en) 2014-05-28 2015-12-03 Piramal Enterprises Limited Pharmaceutical combination for the treatment of cancer

Also Published As

Publication number Publication date
CN105530931A (zh) 2016-04-27
US11839591B2 (en) 2023-12-12
US20240165076A1 (en) 2024-05-23
CA2917742C (en) 2020-04-14
TW202502325A (zh) 2025-01-16
CA2917742A1 (en) 2015-01-15
CN105530931B (zh) 2019-11-08
AR096892A1 (es) 2016-02-03
DK3019166T3 (da) 2019-07-29
JP2021001186A (ja) 2021-01-07
CN111053768A (zh) 2020-04-24
JP2019206565A (ja) 2019-12-05
TW202031253A (zh) 2020-09-01
TW201534297A (zh) 2015-09-16
US12383530B2 (en) 2025-08-12
CN117731786A (zh) 2024-03-22
ES2733929T3 (es) 2019-12-03
TWI839690B (zh) 2024-04-21
AU2014288857A1 (en) 2016-02-04
AU2014288857B2 (en) 2019-03-14
TWI680760B (zh) 2020-01-01
US20190282544A1 (en) 2019-09-19
JP2022068335A (ja) 2022-05-09
EP3019166B1 (en) 2019-05-08
EP3019166A1 (en) 2016-05-18
JP6568060B2 (ja) 2019-08-28
US11007174B2 (en) 2021-05-18
US20160136132A1 (en) 2016-05-19
IL243572A0 (en) 2016-02-29
EP3019166A4 (en) 2017-04-19
TW202233177A (zh) 2022-09-01
WO2015004636A1 (en) 2015-01-15
JP2024037891A (ja) 2024-03-19
JP2016525097A (ja) 2016-08-22
US20210393589A1 (en) 2021-12-23
CN111053768B (zh) 2023-12-12

Similar Documents

Publication Publication Date Title
IL243572A0 (en) Drug combination for the treatment of melanoma
GB201322602D0 (en) Pharmaceutical compounds
IL240846A0 (en) drug combination
GB201306610D0 (en) Pharmaceutical compounds
EP3021848A4 (en) Treatment for melanoma
ZA201602047B (en) Pharmaceutical compounds
GB201308440D0 (en) Therapeutic
ZA201507576B (en) Pharmaceutical combination drug
GB201312155D0 (en) Therapeutic invention
GB201318668D0 (en) Sonosensitive therapeutic
GB201312386D0 (en) Pharmaceutical compounds
EP2948129A4 (en) THERAPEUTIC COMPOUNDS
GB201314286D0 (en) Therapeutic Compounds
GB201312499D0 (en) Therapeutic compounds
HK40102341A (zh) 用於治疗黑素瘤的药物组合
GB201317166D0 (en) Pharmaceutical compounds
GB201320905D0 (en) Therapeutic compounds
GB201316662D0 (en) Pharmaceutical Combination
GB201316780D0 (en) Pharmaceutical compounds
GB201316791D0 (en) Pharmaceutical Compounds
GB201315734D0 (en) Pharmaceutical compounds
GB201315733D0 (en) Pharmaceutical compounds
GB201312464D0 (en) Pharmaceutical compounds
GB201308781D0 (en) Pharmaceutical compounds
GB201308782D0 (en) Pharmaceutical compounds

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed